Anti-NMDAR encephalitis: A single-center, longitudinal study in China.

Xiaolu XuQiang LuYan HuangSiyuan FanLixin ZhouJing YuanXunzhe YangHaitao RenDawei SunYi DaiHuadong ZhuYinan JiangYicheng ZhuBin PengLiying CuiHongzhi Guan

Published in: Neurology(R) neuroimmunology & neuroinflammation (2019)

Patients in China present with psychosis and seizure frequently but have a low percentage of underlying neoplasms. Re-enforced first-line immunotherapy is effective in managing anti-NMDAR encephalitis in the acute phase. Although relapse is relatively common, with combined first-line and long-term immunotherapy, most patients reached favorable outcomes.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes
adipose tissue
weight loss
patient reported
insulin resistance